MRNA vs TECH — Key Metrics

Metric MRNA (MODERNA INC) TECH (BIO-TECHNE CORP)
Price196.7972.75
Market Cap79.63 Billion11.43 Billion
P/E (TTM)-27.866.14
P/B (Quarterly)15.0435.284
P/S (TTM)31.539.3
Net Profit Margin (TTM)-110.514.0
Gross Margin (TTM)28.065.8
ROE (TTM)-37.68.2
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

MODERNA INC
vs
 
BIO-TECHNE CORP
 
MODERNA INC
vs
 
BIO-TECHNE CORP
Performance Comparison
AI Model Recommendation
MRNA · MODERNA INC

Greatly Underperform

-94
UnderperformOutperform
TECH · BIO-TECHNE CORP

Underperform

-43
UnderperformOutperform
Recommendation Summary

Stock MRNA is projected to greatly underperform the market, stock TECH is projected to underperform the market. Upfront Recommendation: TECH.

Financial Metrics
Prices delayed ~15 min
MRNA Metrics TECH
$196.79 Price $72.75
— Market Capitalization —
31.53 Price to Sales 9.3
112.62 Price to Gross Profit 14.15
29.96 Price to R&D 117.98
10.84 Price to Current Assets 13.86

MRNA vs TECH at a glance

Moderna INC (MRNA) and Bio-techne Corp (TECH) are both Biotechnology companies in the Healthcare sector. MRNA is the larger, at $79.6 billion in market value against $11.4 billion for TECH, about 7.0 times the size.

On trailing-twelve-month figures, MRNA trades at 31.5 times trailing sales and TECH at 9.3; net profit margins are -110.5% and 14.0%.

The Upfront Investment model currently rates MRNA Greatly Underperform and TECH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.